Acumen Pharmaceuticals Statistics
Total Valuation
ABOS has a market cap or net worth of $138.71 million. The enterprise value is $2.65 million.
Important Dates
The next estimated earnings date is Tuesday, November 11, 2025, before market open.
| Earnings Date | Nov 11, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
ABOS has 60.57 million shares outstanding. The number of shares has increased by 3.87% in one year.
| Current Share Class | 60.57M |
| Shares Outstanding | 60.57M |
| Shares Change (YoY) | +3.87% |
| Shares Change (QoQ) | +0.08% |
| Owned by Insiders (%) | 10.92% |
| Owned by Institutions (%) | 33.24% |
| Float | 35.61M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 1.18 |
| P/TBV Ratio | 1.18 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio History Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 5.97, with a Debt / Equity ratio of 0.26.
| Current Ratio | 5.97 |
| Quick Ratio | 5.79 |
| Debt / Equity | 0.26 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -34.84 |
Financial Efficiency
Return on equity (ROE) is -75.71% and return on invested capital (ROIC) is -42.77%.
| Return on Equity (ROE) | -75.71% |
| Return on Assets (ROA) | -39.06% |
| Return on Invested Capital (ROIC) | -42.77% |
| Return on Capital Employed (ROCE) | -97.92% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$2.24M |
| Employee Count | 61 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -21.03% in the last 52 weeks. The beta is 0.20, so ABOS's price volatility has been lower than the market average.
| Beta (5Y) | 0.20 |
| 52-Week Price Change | -21.03% |
| 50-Day Moving Average | 1.65 |
| 200-Day Moving Average | 1.36 |
| Relative Strength Index (RSI) | 63.32 |
| Average Volume (20 Days) | 458,808 |
Short Selling Information
The latest short interest is 1.33 million, so 2.20% of the outstanding shares have been sold short.
| Short Interest | 1.33M |
| Short Previous Month | 1.31M |
| Short % of Shares Out | 2.20% |
| Short % of Float | 3.74% |
| Short Ratio (days to cover) | 2.70 |
Income Statement
| Revenue | n/a |
| Gross Profit | -124.21M |
| Operating Income | -143.98M |
| Pretax Income | -136.67M |
| Net Income | -136.67M |
| EBITDA | -143.92M |
| EBIT | -143.98M |
| Earnings Per Share (EPS) | -$2.27 |
Full Income Statement Balance Sheet
The company has $143.37 million in cash and $30.10 million in debt, giving a net cash position of $136.07 million or $2.25 per share.
| Cash & Cash Equivalents | 143.37M |
| Total Debt | 30.10M |
| Net Cash | 136.07M |
| Net Cash Per Share | $2.25 |
| Equity (Book Value) | 117.08M |
| Book Value Per Share | 1.93 |
| Working Capital | 123.54M |
Full Balance Sheet Cash Flow
In the last 12 months, operating cash flow was -$117.76 million and capital expenditures -$88,000, giving a free cash flow of -$117.85 million.
| Operating Cash Flow | -117.76M |
| Capital Expenditures | -88,000 |
| Free Cash Flow | -117.85M |
| FCF Per Share | -$1.95 |
Full Cash Flow Statement Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
ABOS does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -3.87% |
| Shareholder Yield | -3.87% |
| Earnings Yield | -98.52% |
| FCF Yield | -84.96% |
Analyst Forecast
The average price target for ABOS is $8.00, which is 249.35% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $8.00 |
| Price Target Difference | 249.35% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 3 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock Forecasts Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |